Efficacy of Nebulized Liposomal Amphotericin B in Treatment of Experimental Pulmonary Aspergillosis-Reference-Cited by-同舟云学术

Efficacy of Nebulized Liposomal Amphotericin B in Treatment of Experimental Pulmonary Aspergillosis

Published:2005-07 Issue:7 Volume:49 Page:3028-3030
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Gavaldà Joan¹,Martín María-Teresa¹,López Pedro¹,Gomis Xavier¹,Ramírez José-Luís¹,Rodríguez Dolors¹,Len Oscar¹,Puigfel Yolanda¹,Ruíz Isabel¹,Pahissa Albert¹

Affiliation:

1. Infectious Diseases Research Laboratory, Infectious Diseases Division, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

Abstract

ABSTRACT The efficacy of therapeutic aerosolized amphotericin B (AMB) was studied in a steroid-immunosuppressed murine model of invasive pulmonary aspergillosis. Nebulized liposomal AMB can be a valid approach to the treatment of this infection, with subjects showing significantly improved survival relative to that of subjects given intravenous deoxycholate AMB, as well as lower lung weights and pulmonary glucosamine levels.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.49.7.3028-3030.2005

Reference19 articles.

1. Allen, S. D., K. N. Sorensen, M. J. Nejdl, C. Durrant, and R. T. Proffit. 1994. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J. Antimicrob. Chemother.34:1001-1013.

2. Becker, M. J., S. de Marie, M. H. Fens, W. C. Hop, H. A. Verbrugh, and I. A. Bakker-Woudenberg. 2002. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of AmBisome with Fungizone as assessed by several parameters of antifungal response. J. Antimicrob. Chemother.49:813-820.

3. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis

4. Denning, D. W. 1998. Invasive aspergillosis. Clin. Infect. Dis.26:781-805.

5. Denning, D. W., C. C. Kibler, and R. A. Barnes on behalf of the British Society for Medical Mycology. 2003. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect. Dis.3:230-240.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application and evaluation of topical amphotericin B for the treatment of respiratory fungal infections;BMC Infectious Diseases;2024-04-24

2. Nanomaterial-based therapeutics for enhanced antifungal therapy;Journal of Materials Chemistry B;2024

3. LIPOSOMAL DRY POWDER INHALER: NOVEL PULMONARY TARGETED DRUG DELIVERY SYSTEM FOR THE TREATMENT OF LUNG CANCER;International Journal of Applied Pharmaceutics;2023-01-07

4. Inhaled Antifungal Agents for Treatment and Prophylaxis of Bronchopulmonary Invasive Mold Infections;Pharmaceutics;2022-03-14

5. Successful Treatment of Antifungal Combination Therapy with Inhaled Liposomal Amphotericin B and Oral Voriconazole for Intractable Chronic Progressive Pulmonary Aspergillosis;Internal Medicine;2021-08-01